These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 36062966)

  • 1. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
    Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3378-3388. PubMed ID: 36062966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.
    Miller BS; Blair JC; Rasmussen MH; Maniatis A; Mori J; Böttcher V; Kim HS; Bang RB; Polak M; Horikawa R
    J Clin Endocrinol Metab; 2023 Nov; 108(12):3090-3099. PubMed ID: 37406251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.
    Mori J; Ohata Y; Fujisawa Y; Sato Y; Röhrich S; Rasmussen MH; Bang RB; Horikawa R
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):389-398. PubMed ID: 38368603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
    Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
    Garner T; Clayton P; Højby M; Murray P; Stevens A
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
    Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.
    Johannsson G; Feldt-Rasmussen U; Håkonsson IH; Biering H; Rodien P; Tahara S; Toogood A; Rasmussen MH;
    Eur J Endocrinol; 2018 May; 178(5):491-499. PubMed ID: 29500310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.
    Otsuka F; Takahashi Y; Tahara S; Ogawa Y; Højby Rasmussen M; Takano K
    Clin Endocrinol (Oxf); 2020 Nov; 93(5):620-628. PubMed ID: 32603494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study.
    Juul A; Backeljauw P; Højby M; Kawai M; Kildemoes RJ; Linglart A; Zuckerman-Levin N; Horikawa R
    Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Somapacitan Relative to Somatrogon and Lonapegsomatropin in Pediatric Growth Hormone Deficiency: Systematic Literature Review and Network Meta-analysis.
    de Fries Jensen L; Antavalis V; Odgaard-Jensen J; Rossi A; Pietropoli A; Højby M
    Adv Ther; 2024 Nov; 41(11):4098-4124. PubMed ID: 39261416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somapacitan in Children Born SGA: 52-week Efficacy, Safety, and IGF-I Response Results from the Phase 2 REAL5 Study.
    Juul A; Backeljauw P; Højby M; Frystyk J; Kawai M; Kildemoes RJ; Lemminger AK; Linglart A; Zuckerman-Levin N; Horikawa R
    J Clin Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39271158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.
    Tsurayya G; Nazhifah CA; Pirwanja MR; Zulfa PO; Tatroman MRR; Fakri F; Iqhrammullah M
    Children (Basel); 2024 Feb; 11(2):. PubMed ID: 38397339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency.
    Kildemoes RJ; Backeljauw PF; Højby M; Blair JC; Miller BS; Mori J; Lyauk YK
    J Endocr Soc; 2023 Oct; 7(11):bvad115. PubMed ID: 37818403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment.
    Zadik Z; Zelinska N; Iotova V; Skorodok Y; Malievsky O; Mauras N; Valluri SR; Pastrak A; Rosenfeld R
    J Pediatr Endocrinol Metab; 2023 Mar; 36(3):261-269. PubMed ID: 36732285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
    Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
    Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
    Takahashi Y; Biller BMK; Fukuoka H; Ho KKY; Rasmussen MH; Nedjatian N; Sværke C; Yuen KCJ; Johannsson G
    Pituitary; 2023 Feb; 26(1):57-72. PubMed ID: 36380045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.